BLAINJECTIONINJECTABLEPriority Review
Approved
Sep 2018
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
4/8 — Partial
Priority Review
AJOVY (fremanezumab-vfrm) by Teva is fremanezumab-vfrm is a humanized monoclonal antibody that binds to calcitonin gene-related peptide (cgrp) ligand and blocks its binding to the receptor. First approved in 2018.
Drug data last refreshed 17h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
AJOVY (fremanezumab-vfrm) is a humanized monoclonal antibody approved by the FDA in September 2018 for migraine prevention. It blocks calcitonin gene-related peptide (CGRP) ligand, preventing its binding to the receptor and reducing migraine frequency. The drug represents a novel mechanism in the migraine therapeutic class.
Peak
Peak-stage product with moderate competitive pressure (30/100) suggests mature commercial infrastructure and stable team sizing.
Mechanism of Action
Fremanezumab-vfrm is a humanized monoclonal antibody that binds to calcitonin gene-related peptide (CGRP) ligand and blocks its binding to the receptor.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Specified Drug Use Survey on AJOVY Subcutaneous Injection for Long-term Use
Started Apr 2022
1,000 enrolled
Migraine Disorders
Career Relevance
AJOVY is a peak-stage monoclonal antibody in a competitive migraine market, offering stable career opportunities in commercial strategy, medical affairs, and field execution. Working on AJOVY provides experience in competitive biologic management, specialty care channels, and neurology-focused disease states.
Brand Manager
Worked on AJOVY at Teva? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.